Navigation Links
Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S.
Date:9/23/2010

Reata PharmaceuticalsReata Pharmaceuticals is the leader in discovering and developing novel, oral anti-inflammatory drugs that activate Nrf2, the primary regulator of cellular antioxidant and detoxification enzymes.  Activation of this important biological target protects against a broad range of diseases associated with inflammation and oxidative stress.  Reata is developing bardoxolone methyl, its lead product candidate, as the first disease-modifying treatment for chronic kidney disease.  In January 2010, Reata and Kyowa Hakko Kirin announced a licensing agreement providing KHK with the exclusive rights to develop and commercialize bardoxolone in Japan and other selected Asian markets.

For more information please visit the company's Web site at www.reatapharma.com.

About Abbott LaboratoriesAbbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs nearly 90,000 people and markets its products in more than 130 countries.  

Abbott's news releases and other information are available on the company's Web site at www.abbott.com

Abbott Forward Looking Statement Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors," to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2009, and in Item 1A, "Risk
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... 2014  Uroplasty, Inc. (NASDAQ: UPI ), ... markets innovative proprietary products to treat voiding dysfunctions, ... first quarter ended June 30, 2014.  Global ... System grew 19% to $4.1 million, as compared ... the prior year.  Total revenue for the fiscal ...
(Date:7/24/2014)... Calif. , July 24, 2014 Amgen (NASDAQ: ... its second quarter financial results on Tuesday, July 29, 2014, ... will be followed by a conference call with the investment ... Amgen will be Robert A. Bradway , chairman and ... team. Live audio of the conference call will ...
Breaking Medicine Technology:Uroplasty Reports Fiscal First Quarter Results 2Uroplasty Reports Fiscal First Quarter Results 3Uroplasty Reports Fiscal First Quarter Results 4Uroplasty Reports Fiscal First Quarter Results 5Uroplasty Reports Fiscal First Quarter Results 6Uroplasty Reports Fiscal First Quarter Results 7Uroplasty Reports Fiscal First Quarter Results 8Uroplasty Reports Fiscal First Quarter Results 9Uroplasty Reports Fiscal First Quarter Results 10Uroplasty Reports Fiscal First Quarter Results 11Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
(Date:7/26/2014)... July 26, 2014 Recently, iFitDress.com, a ... for women, has unveiled its new range of high ... offer on the brand new items; they are now ... , iFitDress.com is one of the leading suppliers ... officer, all the wholesale party dresses have ...
(Date:7/26/2014)... Dallas,Texas (PRWEB) July 26, 2014 “BRIC ... on the BRIC Sinuscopes market. The report provides value, ... average prices (in US dollars) within market segments – ... shares and distribution shares data for each of these ... market participants, pipeline products, and news and deals related ...
(Date:7/26/2014)... TX (PRWEB) July 26, 2014 ... or encephalomyelitis disseminata, is an inflammatory disease in ... the brain and spinal cord are damaged. This ... nervous system to communicate, resulting in a wide ... and sometimes psychiatric problems. Multiple sclerosis takes several ...
(Date:7/26/2014)... Seattle, Wa (PRWEB) July 26, 2014 ... updated by Vkool.com, this is a comprehensive bodybuilding program ... simultaneously without using anabolic steroids . The program ... lean muscle without cardio. , Vkool reveals in ... exercises and workouts that can help men get ripped ...
(Date:7/25/2014)... Dental Perfection, a Derby cosmetic dentist ... general dentistry, clear braces and much more, has just ... in Derby. The new practice, which is scheduled to ... in Littleover, Derby. Patients may already pre-register for the ... dental practice, which is headed by Invisalign specialist and ...
Breaking Medicine News(10 mins):Health News:High Quality Wholesale Party Dresses Online at iFitDress.com 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 2Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 3Health News:Sinuscopes Market in BRIC (Brazil, Russia, India & China) Forecast to 2020 Report Available at MarketOptimizer.org 4Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 2Health News:Metabolic Enhancement Training Review Exposes Scott Abel's Program for Bodybuilding – Vkool.com 3Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2
... in small study took capsules equivalent to brewed beverage, , ... green tea might slow the progression of prostate cancer, the ... 26 men, 41 to 72 years old, who had prostate ... took four capsules a day of an investigational agent called ...
... , Local Vascular Surgeon Named National Principal Investigator , ... from Arizona Heart Institute performed the first procedure in ... Vascutek Anaconda Stent Graft System , an investigational, minimally ... , Leading the study efforts in the U.S. ...
... , DEERFIELD BEACH, Fla., June 19 Sentry Data ... scanning device, Sentinel Mobile Manager(TM), as part of ... feedback and the desire to provide increased value ... with Sentinel RCM,s(TM) core functionality and provides a ...
... BEIJING, June 19 /PRNewswire-Asia-FirstCall/ -- China ... a leading China-based medical device,company that develops, manufactures and ... financial results for,the fourth fiscal quarter (,4Q FY2008,) and ... 2009 (,FY2008,). The Company,s 2008 fiscal year ends ...
... ... readers, AmericanHealthandBeauty.com has added Dysport, formerly known as Reloxin, as a procedure on their website. ... Houston, TX (PRWEB) June ... lines and wrinkles on the face, has recently gained FDA approval and is expected to ...
... (NYSE: SRZ ) today announced that it will transition ... As previously disclosed in its 2008 10-K, Sunrise could be terminated ... to comply with their financial covenants in 2008. HCP announced ... , "While we regret the loss of these communities, it ...
Cached Medicine News:Health News:Green Tea Component May Slow Prostate Cancer 2Health News:Arizona Heart Institute Enrolls First Patient in Anaconda(TM) Investigational Study for the Treatment of Abdominal Aortic Aneurysm 2Health News:Arizona Heart Institute Enrolls First Patient in Anaconda(TM) Investigational Study for the Treatment of Abdominal Aortic Aneurysm 3Health News:Sentry Data Systems, Inc. Announces: Sentinel RCM(TM) - Now with Mobile Manager(TM) Included! 2Health News:China Medical Technologies Announces Selected Unaudited Preliminary Financial Results for the Fourth Fiscal Quarter and Full Year Ended March 31, 2009 2Health News:China Medical Technologies Announces Selected Unaudited Preliminary Financial Results for the Fourth Fiscal Quarter and Full Year Ended March 31, 2009 3Health News:Dysport Added as a Procedure on AmericanHealthandBeauty.com: Let the Wrinkle Wars Begin 2Health News:Dysport Added as a Procedure on AmericanHealthandBeauty.com: Let the Wrinkle Wars Begin 3
... Tissue transglutaminase (tTg) is a ... of proteins. Tissue transglutaminase is also ... by the endomysial antibody immunofluorescence (EMA) ... 29060). Anti-tTg IgA and IgG serologic ...
... training it needs with the NetLearning Management ... Capital Management System in one. Whether it ... and HIPAA, understanding compliance reporting for OSHA, ... through continuing education courses, the NetLearning system ...
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EGG or EMG recordings. Surface Electrodes, Skin Preparation and Conductive Cream complete the setup for a EGG study and are essenti...
Medicine Products: